Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | MMP2 | P08253 | 9/20 | 0.56 |
| ▸ | MMP9 | P14780 | 7/20 | 0.56 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.51 |
| ▸ | MMP1 | P03956 | 1/20 | 0.51 |
| ▸ | MMP3 | P08254 | 1/20 | 0.51 |
| ▸ | MMP7 | P09237 | 1/20 | 0.51 |
| ▸ | MMP13 | P45452 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7239608 | 1.00 | HTT (0.57) | HTTMMP2MMP9ADAMTS4POLB | |
| SCHEMBL4147220 | 0.82 | MMP2 (0.56) | HTTMMP2MMP9ADAMTS4POLB | |
| SCHEMBL27238700 | 0.82 | MMP2 (0.56) | HTTMMP2MMP9ADAMTS4POLB | |
| SCHEMBL5148151 | 0.82 | MMP2 (0.56) | HTTMMP2MMP9ADAMTS4POLB | |
| SCHEMBL14218257 | 0.78 | MMP2 (0.87) | MMP2MMP9ADAMTS4POLBALDH1A1 | |
| SCHEMBL6916882 | 0.77 | MMP2 (0.63) | HTTMMP2MMP9ADAMTS4POLB | |
| SCHEMBL4188026 | 0.76 | MMP2 (0.85) | MMP2MMP9ADAMTS4POLBALDH1A1 | |
| SCHEMBL697591 | 0.76 | MMP2 (0.85) | MMP2MMP9ADAMTS4POLBALDH1A1 | |
| SCHEMBL697592 | 0.76 | MMP2 (0.85) | MMP2MMP9ADAMTS4POLBALDH1A1 | |
| SCHEMBL11950557 | 0.76 | MMP2 (0.62) | HTTMMP2MMP9ADAMTS4POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624157-B2 | Antitumor agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-20010039273-A1 | Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase | DING CHARLES Z (US) | 2001-11-08 | — | — | US | disclosed |
| EP-0918771-A4 | THIADIOXOBENZODIAZEPINE INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL MYERS SQUIBB CO (US) | 2001-02-07 | — | — | EP | disclosed |
| EP-0918771-A1 | THIADIOXOBENZODIAZEPINE INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-06-02 | — | — | EP | disclosed |
| WO-1998002436-A1 | THIADIOXOBENZODIAZEPINE INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039273-A1 | Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase | CBR1, CBR3, FNTB | HTT 4631/4885MMP2 3906/4885MMP9 3761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.